Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial

Cancer is a leading cause of death globally. Given the elevated risk of cancer with age and an ageing population, it is important to understand the changing burden of cancer in older populations. The ASPirin in Reducing Events in the Elderly (ASPREE) study randomised healthy older individuals to 100  mg aspirin or placebo, with clinical outcomes and disability-free survival endpoints. Detailed baseline data provides a rare opportunity to explore cancer burden in a uniquely healthy older population.

Source: Contemporary Clinical Trials - July 29, 2020 Category: Radiology Authors: Suzanne G. Orchard, Jessica E. Lockery, Peter Gibbs, Galina Polekhina, Rory Wolfe, John Zalcberg, Andrew Haydon, John J. McNeil, Mark R. Nelson, Christopher M. Reid, Brenda Kirpach, Anne M. Murray, Robyn L. Woods, ASPREE Investigator Group Source Type: research